vTv Therapeutics Inc. VTVT · Stock Open vTv Therapeutics Inc. in new tab
vTv Therapeutics Inc. Analysis (VTVT)
Is vTv Therapeutics Inc. a good investment? vTv Therapeutics Inc. (VTVT) is currently trading at 31.31 USD. Market analysts have a consensus price target of 54.71 USD. This suggests a potential upside from current levels.
Earnings Schedule: vTv Therapeutics Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -4.29.
Investor FAQ
Does vTv Therapeutics Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is vTv Therapeutics Inc.?
vTv Therapeutics Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -0.75.
Company Profile
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 21, 2023 | 0.03 |
Community Discussion